Psychiatr. praxi. 2021;22(3):150-156 | DOI: 10.36290/psy.2021.032

Tolerability of antidepressants, their multimodal effects and mechanisms of their side effects

doc. PharmDr. Jan Juřica, Ph.D.
Farmakologický ústav LF Brno

Antidepressants represent an essential and effective therapeutic approach in treating depressive disorders and many other neuropsychiatric diseases. This review article summarizes the most common side effects of the most frequently used antidepressants in the Czech Republic. These side effects usually have a rational explanation based on their receptor profile or pharmacokinetics. In this context, the advantages and disadvantages of these selected antidepressants are summarized, especially in terms of tolerability and additive effects.

Keywords: antidepressants, tolerance, trazodone, mirtazapine, vortioxetine, venlafaxin, SSRI.

Published: October 14, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Juřica J. Tolerability of antidepressants, their multimodal effects and mechanisms of their side effects. Psychiatr. praxi. 2021;22(3):150-156. doi: 10.36290/psy.2021.032.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. InfoPharm. AISLP. In.; 2021.
    2. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 2009; 14(10):536-546. Go to original source... Go to PubMed...
    3. Fagiolini A, Comandini A, Catena Dell'Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs 2012; 26(12):1033-1049. Go to original source... Go to PubMed...
    4. Dynamed American Society of Health System Pharmacists I. Dynamed. In., 03-2017 edn. Ipswich (MA): EBSCO Information Services. 1995-2017; 2017.
    5. Price J, Cole V, Goodwin GM. Emotional side‑effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry 2009; 195(3): 211-217. Go to original source... Go to PubMed...
    6. Stahl SM. Multifunctional drugs: a novel concept for psychopharmacology. CNS Spectr 2009; 14(2) :71-73. Go to original source... Go to PubMed...
    7. Stahl SM. Stahl's Essential Psychopharmacology Cambridge University Press; 2013.
    8. ECNP. Neuroscience based nomenclature. In.; 2021.
    9. Hirsch M, Birnbaum RJ. Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects. In: In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. 2021.
    10. Albert U, Lamba P, Stahl SM. Early response to trazodone once‑a‑day in major depressive disorder: review of the clinical data and putative mechanism for faster onset of action. CNS Spectr 2021; 26(3): 232-242. Go to original source... Go to PubMed...
    11. Commons KG, Linnros SE. Delayed Antidepressant Efficacy and the Desensitization Hypothesis. ACS Chem Neurosci 2019; 10(7): 3048-3052. Go to original source... Go to PubMed...
    12. Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? Int Clin Psychopharmacol 2014; 29(4): 185-196. Go to original source... Go to PubMed...
    13. Opal M, Klenotich S, Morais M, Bessa J, Winkle J, Doukas D, Kay L, Sousa N, Dulawa S. Serotonin 2C receptor antagonists induce fast‑onset antidepressant effects. Molecular Psychiatry 2014; 19(10): 1106-1114. Go to original source... Go to PubMed...
    14. Tokarski K, Bobula B, Grzegorzewska‑Hiczwa M, Kusek M, Hess G. Stress- and antidepressant treatment‑induced modifications of 5-HT7 receptor functions in the rat brain. Pharmacological Reports 2012; 64(6): 1305-1315. Go to original source... Go to PubMed...
    15. Rancans E, Zambori J, Dalsgaard M, Baayen C, Areberg J, Ettrup A, Florea I. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double‑blind, placebo‑controlled exploratory study. International Clinical Psychopharmacology 2020; 35(6): 305-312. Go to original source... Go to PubMed...
    16. Sinclair LI, Christmas DM, Hood SD, Potokar JP, Robertson A, Isaac A, Srivastava S, Nutt DJ, Davies SJ. Antidepressant‑induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry 2009; 194(6): 483-490. Go to original source... Go to PubMed...
    17. Harada T, Inada K, Yamada K, Sakamoto K, Ishigooka J. A prospective naturalistic study of antidepressant‑induced jitteriness/anxiety syndrome. Neuropsychiatr Dis Treat 2014; 10: 2115-2121. Go to original source... Go to PubMed...
    18. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 2003; 53(3): 193-203. Go to original source... Go to PubMed...
    19. Orsolini L, Tomasetti C, Valchera A, Iasevoli F, Buonaguro EF, Vellante F, Fornaro M, Fiengo A, Mazza M, Vecchiotti R et al. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Expert Rev Neurother 2016; 16(5): 483-495. Go to original source... Go to PubMed...
    20. Salvi V, Mencacci C, Barone‑Adesi F. H1-histamine receptor affinity predicts weight gain with antidepressants. Eur Neuropsychopharmacol 2016; 26(10): 1673-1677. Go to original source... Go to PubMed...
    21. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta‑analysis. J Clin Psychiatry 2010; 71(10): 1259-1272. Go to original source... Go to PubMed...
    22. Gill H, Gill B, El‑Halabi S, Chen‑Li D, Lipsitz O, Rosenblat JD, Van Rheenen TE, Rodrigues NB, Mansur RB, Majeed A et al. Antidepressant Medications and Weight Change: A Narrative Review. Obesity (Silver Spring) 2020; 28(11): 2064-2072. Go to original source... Go to PubMed...
    23. Duncan NA, Clifford KM, Shvarts OM. Mirtazapine‑Associated Hypertriglyceridemia and Hyperglycemia. Consult Pharm 2015; 30(11): 657-663. Go to original source... Go to PubMed...
    24. Himmerich H, Fulda S, Schaaf L, Beitinger PA, Schuld A, Pollmächer T. Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care 2006; 29(1): 170. Go to original source...
    25. Zourkova A, Ceskova E, Hadasova E, Ravcukova B. Links among paroxetine‑induced sexual dysfunctions, gender, and CYP2D6 activity. Journal of Sex & Marital Therapy 2007; 33(4): 343-355. Go to original source... Go to PubMed...
    26. Stahl S. Mechanism of action of serotonin selective reuptake inhibitors - Serotonin receptors and pathways mediate therapeutic effects and side effects. Journal of Affective Disorders 1998; 51(3): 215-235. Go to original source... Go to PubMed...
    27. Stryjer R, Spivak B, Strous R, Shiloh R, Harary E, Polak L, Birgen M, Kotler M, Weizman A. Trazodone for the Treatment of Sexual Dysfunction Induced by Serotonin Reuptake Inhibitors: A Preliminary Open‑Label Study. Clinical Neuropharmacology 2009; 32(2): 82-84. Go to original source... Go to PubMed...
    28. Zourkova A, Novotna J, Vecerova M, Havlikova P, Pulkrabkova L. Occurrence of sexual dysfunction during the maintenance treatment with newer antidepressants (naturalistic study). European Neuropsychopharmacology 2008; 18: S375-S376. Go to original source...
    29. Rizvi SJ, Kennedy SH. Management strategies for SSRI‑induced sexual dysfunction. J Psychiatry Neurosci 2013; 38(5): E27-28. Go to original source... Go to PubMed...
    30. Jacobsen PL, Mahableshwarkar AR, Palo WA, Chen Y, Dragheim M, Clayton AH. Treatment‑emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. CNS Spectr 2016; 21(5): 367-378. Go to original source... Go to PubMed...
    31. Rosenberg I, Aniskin D. Bernay L. Psychiatric treatment of patients predisposed to priapism induced by quetapine, trazadone and risperidone: a case report. Gen Hosp Psychiatry, 2009; 31(1): 98. Go to original source... Go to PubMed...
    32. Sharma TR. Priapism lasting 19 hours with combined use of trazodone and mirtazapine in a patient with history of successfully tolerating each agent as monotherapy. Prim Care Companion CNS Disord 2012; 14(5). Go to original source... Go to PubMed...
    33. de Tejada IS, Ware JC, Blanco R, Pittard JT, Nadig PW, Azadzoi KM, Krane RJ, Goldstein I. Pathophysiology of prolonged penile erection associated with trazodone use J Urol. 1991; 145(1): 60-64. Go to original source... Go to PubMed...
    34. Hoehn‑Saric R, Lipsey JR, McLeod Dr. Apathy and indifference in patients on fluvoxamine and fluoxetine. J Clin Psychopharmacol 1990; 10(5): 343-345. Go to original source... Go to PubMed...
    35. Sansone RA, Sansone LA. SSRI‑Induced Indifference. Psychiatry (Edgmont) 2010; 7(10): 14-18.
    36. Marazziti D, Mucci F, Tripodi B, Carbone M, Muscarella A, Falaschi V, Baroni S. Emotional blunting, cognitive impairment, bone fractures, and bleedingg as possible side effects of lond‑therm use of SSRls. Clinical Neuropsychiatry 2019; 16(2): 75-85.
    37. Goodwin GM, Price J, De Bodinat C, Laredo J. Emotional blunting with antidepressant treatments: A survey among depressed patients. J Affect Disord 2017; 221: 31-35. Go to original source... Go to PubMed...
    38. Kennedy SH, Javanmard M, Vaccarino FJ. A review of functional neuroimaging in mood disorders: positron emission tomography and depression. Can J Psychiatry 1997, 42(5): 467-475. Go to original source... Go to PubMed...
    39. Opbroek A, Delgado PL, Laukes C, McGahuey C, Katsanis J, Moreno FA, Manber R. Emotional blunting associated with SSRI‑induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol 2002; 5(2): 147-151. Go to original source... Go to PubMed...
    40. Burke MV, Nocjar C, Sonneborn AJ, McCreary AC, Pehek EA. Striatal serotonin 2C receptors decrease nigrostriatal dopamine release by increasing GABA‑A receptor tone in the substantia nigra. J Neurochem 2014; 131(4): 432-443. Go to original source... Go to PubMed...
    41. Di Giovanni G, De Deurwaerdére P, Di Mascio M, Di Matteo V, Esposito E, Spampinato U. Selective blockade of serotonin-2C/2 B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 1999; 91(2): 587-597. Go to original source... Go to PubMed...
    42. Di Matteo V, Di Giovanni G, Pierucci M, Esposito E. Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies. Prog Brain Res 2008; 172: 7-44. Go to original source... Go to PubMed...
    43. Millan MJ, Dekeyne A, Gobert A. Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 1998; 37(7): 953-955. Go to original source... Go to PubMed...
    44. Chagraoui A, Thibaut F, Skiba M, Thuillez C, Bourin M: 5-HT2C receptors in psychiatric disorders. A review. Progress in Neuro‑Psychopharmacology & Biological Psychiatry 2016; 66: 120-135. Go to original source... Go to PubMed...
    45. Hoschl C. Serotoninergní mechanismy účinku multifunkčních antidepresiv a některých antipsychotik. Psychiatrie 2015; 19(1): 44-48.
    46. Fagiolini A, Florea I, Loft H, Christensen MC. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment. J Affect Disord 2021; 283: 472-479. Go to original source... Go to PubMed...
    47. Holshoe JM. Antidepressants and sleep: a review. Perspect Psychiatr Care 2009; 45(3): 191-197. Go to original source... Go to PubMed...
    48. Hutka P, Krivosova M, Muchova Z, Tonhajzerova I, Hamrakova A, Mlyncekova Z, Mokry J, Ondrejka I. Association of Sleep Architecture and Physiology with Depressive Disorder and Antidepressants Treatment. International Journal of Molecular Sciences 2021; 22(3). Go to original source... Go to PubMed...
    49. Schweitzer PK. Drugs That Disturb Sleep and Wakefulnes. In: Principles and Practice of Sleep Medicine, 5th Editions. Edited by Kryger MH; 2011: 542-560. Go to original source...
    50. Kerkhofs M, Mendlewicz J. The effects of antidepressant treatment on sleep disturbances in depression. European Psychiatry 1995; 10(8): 391-396. Go to original source... Go to PubMed...
    51. Shigemoto Y, Fujii Y, Shinomiya K, Kamei C. Participation of histaminergic H1 and noradrenergic alpha 1 receptors in orexin A‑induced wakefulness in rats. Brain Res 2004; 1023(1): 121-125. Go to original source... Go to PubMed...
    52. Morera AL, Abreu‑Gonzalez P, Henry M, Garcia‑Hernandez A. Trazodone hypnotic effect and nocturnal melatonin secretion. J Clin Psychopharmacol 2009; 29(1): 97-99. Go to original source... Go to PubMed...
    53. Giannaccini G, Masala I, Palego L, Betti L, Pacciardi B, Palagini L, Luchini F, Belli S, Lucacchini A, Mauri M. Melatonin and pro‑hypnotic effectiveness of the antidepressant Trazodone: A preliminary evaluation in insomniac mood‑disorder patients. Clinical Biochemistry 2016; 49(15): 1152-1158. Go to original source... Go to PubMed...
    54. Mawardi G, Markman TM, Muslem R, Sobhanian M, Converse M, Meadows HB, Uber WE, Russell SD, Rouf R, Ramu B et al. SSRI/SNRI Therapy is Associated With a Higher Risk of Gastrointestinal Bleeding in LVAD Patients. Heart Lung Circ 2020; 29(8): 1241-1246. Go to original source... Go to PubMed...
    55. Turner MS, May DB, Arthur RR, Xiong GL. Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks. J Intern Med 2007; 261(3): 205-213. Go to original source... Go to PubMed...
    56. Laporte S, Chapelle C, Caillet P, Beyens MN, Bellet F, Delavenne X, Mismetti P, Bertoletti L. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta‑analysis of observational studies. Pharmacol Res 2017; 118: 19-32. Go to original source... Go to PubMed...
    57. Lewis J, Strom B, Localio A, Metz D, Farrar J, Weinrieb R, Nessel L, Brensinger C, Kimmel S. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. Pharmacoepidemiology and Drug Safety 2008; 17(4): 328-335. Go to original source... Go to PubMed...
    58. Castro V, Gallagher P, Clements C, Murphy S, Gainer V, Fava M, Weilburg J, Churchil S, Kohane I, Iosifescu D et al. Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants. Bmj Open 2012; 2(2). Go to original source... Go to PubMed...
    59. Bixby AL, VandenBerg A, Bostwick JR. Clinical Management of Bleeding Risk With Antidepressants. Ann Pharmacother 2019; 53(2): 186-194. Go to original source... Go to PubMed...
    60. Chung K. Rapid onset of hemoptysis in a young man treated with vortioxetine. Psychiatry and Clinical Neurosciences 2021. Go to original source...
    61. Hudd TR, Blake CS, Rimola‑Dejesus Y, Nguyen TT, Zaiken K. A Case Report of Serotonin Syndrome in a Patient on Selective Serotonin Reuptake Inhibitor (SSRI) Monotherapy. J Pharm Pract 2020; 33(2): 206-212. Go to original source... Go to PubMed...
    62. Liu Y, Yang H, He F, Xu P, Tong H, Ni J, Zhang Q, Wang J. An atypical case of serotonin syndrome with normal dose of selective serotonin inhibitors: A case report. Medicine (Baltimore) 2019; 98(19): e15554. Go to original source... Go to PubMed...
    63. Boyer EW. Serotonin syndrome (serotonin toxicity). In.: UpToDate, Post TW (Ed), UpToDate, Waltham, MA.; 2021.
    64. Francescangeli J, Karamchandani K, Powell M, Bonavia A. The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice. Int J Mol Sci 2019; 20(9). Go to original source... Go to PubMed...
    65. Ubogu EE, Katirji B. Mirtazapine‑induced serotonin syndrome. Clin Neuropharmacol 2003; 26(2): 54-57. Go to original source... Go to PubMed...
    66. Berling I, Isbister GK. Mirtazapine overdose is unlikely to cause major toxicity. Clin Toxicol (Phila) 2014; 52(1): 20-24. Go to original source... Go to PubMed...
    67. Isbister GK, Whyte IM. Adverse reactions to mirtazapine are unlikely to be serotonin toxicity. Clin Neuropharmacol 2003; 26(6): 287-288; author reply 289-290. Go to original source... Go to PubMed...
    68. Prapotnik M, Waschgler R, König P, Moll W, Conca A. Therapeutic drug monitoring of trazodone: are there pharmacokinetic interactions involving citalopram and fluoxetine? Int J Clin Pharmacol Ther 2004; 42(2): 120-124. Go to original source... Go to PubMed...
    69. Assimon MM, Brookhart MA, Flythe JE. Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis. J Am Soc Nephrol 2019; 30(4): 611-623. Go to original source... Go to PubMed...
    70. Bavle A. Venlafaxine induced QTc interval prolongation in a therapeutic dose. Asian J Psychiatr 2015; 16: 63-64. Go to original source... Go to PubMed...
    71. Jasiak NM, Bostwick JR. Risk of QT/QTc prolongation among newer non‑SSRI antidepressants. Ann Pharmacother 2014; 48(12): 1620-1628. Go to original source... Go to PubMed...
    72. Soe KK, Lee MY. Arrhythmias in Severe Trazodone Overdose. Am J Case Rep 2019; 20: 1949-1955. Go to original source... Go to PubMed...
    73. Armstrong SEM, Brown HK, Shorey C, Madan R, Szabuniewicz C, Koh S, Crépeau‑Gendron G, Mah L. No Association Between Trazodone and Corrected‑QT Prolongation in Older Adults. J Clin Psychopharmacol 2019, 39(5): 528-530. Go to original source... Go to PubMed...
    74. Bordet C, Rousseau V, Montastruc F, Montastruc JL. QT prolongation and vortioxetine: a post‑marketing study and comparison with other serotonin reuptake inhibitors. Psychopharmacology (Berl) 2020; 237(4): 1245-1247. Go to original source... Go to PubMed...
    75. UpToDate. In. UpToDate, Waltham, MA.; 2021.
    76. Bossini L, Coluccia A, Casolaro I, Benbow J, Amodeo G, De Giorgi R, Fagiolini A. Off‑Label Trazodone Prescription: Evidence, Benefits and Risks. Curr Pharm Des 2015; 21(23): 3343-3351. Go to original source... Go to PubMed...
    77. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995; 10 Suppl 4: 37-45. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.